These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 6429195)
1. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. Fick RB; Naegel GP; Squier SU; Wood RE; Gee JB; Reynolds HY J Clin Invest; 1984 Jul; 74(1):236-48. PubMed ID: 6429195 [TBL] [Abstract][Full Text] [Related]
2. Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase. Bainbridge T; Fick RB J Lab Clin Med; 1989 Dec; 114(6):728-33. PubMed ID: 2512365 [TBL] [Abstract][Full Text] [Related]
3. Pseudomonas respiratory infection in cystic fibrosis: a possible defect in opsonic IgG antibody? Fick RB; Reynolds HY Bull Eur Physiopathol Respir; 1983; 19(2):151-61. PubMed ID: 6871494 [TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Fick RB; Olchowski J; Squier SU; Merrill WW; Reynolds HY Am Rev Respir Dis; 1986 Mar; 133(3):418-22. PubMed ID: 3082264 [TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. Fick RB; Naegel GP; Matthay RA; Reynolds HY J Clin Invest; 1981 Oct; 68(4):899-914. PubMed ID: 6793632 [TBL] [Abstract][Full Text] [Related]
6. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Fick RB; Robbins RA; Squier SU; Schoderbek WE; Russ WD Pediatr Res; 1986 Dec; 20(12):1258-68. PubMed ID: 3540828 [TBL] [Abstract][Full Text] [Related]
7. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330 [TBL] [Abstract][Full Text] [Related]
8. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion. Hornick DB; Fick RB J Clin Invest; 1990 Oct; 86(4):1285-92. PubMed ID: 2120286 [TBL] [Abstract][Full Text] [Related]
9. Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Moss RB; Hsu YP; Sullivan MM; Lewiston NJ Pediatr Res; 1986 May; 20(5):453-9. PubMed ID: 3714355 [TBL] [Abstract][Full Text] [Related]
10. Correlation between specific IgG subclass antibodies to Pseudomonas aeruginosa and opsonic activity in serum from patients with cystic fibrosis. Pressler T; Jensen ET; Espersen F; Pedersen SS; Høiby N; Koch C Pediatr Pulmonol; 1994 Jan; 17(1):31-40. PubMed ID: 8108174 [TBL] [Abstract][Full Text] [Related]
11. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. Fick RB; Baltimore RS; Squier SU; Reynolds HY J Infect Dis; 1985 Apr; 151(4):589-98. PubMed ID: 3919115 [TBL] [Abstract][Full Text] [Related]
12. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary host defense: defects that lead to chronic inflammation of the airway. Hornick DB Clin Chest Med; 1988 Dec; 9(4):669-78. PubMed ID: 3148383 [TBL] [Abstract][Full Text] [Related]
14. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis. Marshall BC; Carroll KC Semin Respir Infect; 1991 Mar; 6(1):11-8. PubMed ID: 1909452 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the adherence of Pseudomonas aeruginosa to epithelial cells by IgG subclass antibodies. Morrin M; Reen DJ J Med Microbiol; 1993 Dec; 39(6):459-66. PubMed ID: 8246266 [TBL] [Abstract][Full Text] [Related]
16. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
17. Tissue-specific Fc gamma and complement receptor expression by alveolar macrophages determines relative importance of IgG and complement in promoting phagocytosis of Pseudomonas aeruginosa. Berger M; Norvell TM; Tosi MF; Emancipator SN; Konstan MW; Schreiber JR Pediatr Res; 1994 Jan; 35(1):68-77. PubMed ID: 8134202 [TBL] [Abstract][Full Text] [Related]
18. The role of IgG subclass antibodies in chronic infection: the case of cystic fibrosis. Moss RB N Engl Reg Allergy Proc; 1988; 9(1):57-61. PubMed ID: 3362109 [TBL] [Abstract][Full Text] [Related]
19. Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kDa GroEL in prediabetic patients with cystic fibrosis. Jensen P; Johansen HK; Lanng S; Høiby N Pediatr Res; 2001 Mar; 49(3):423-8. PubMed ID: 11228271 [TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa. McCormick LL; Karulin AY; Schreiber JR; Greenspan NS J Immunol; 1997 Apr; 158(7):3474-82. PubMed ID: 9120309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]